Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunocore Holdings (IMCR) Operating Leases (2019 - 2025)

Immunocore Holdings' Operating Leases history spans 4 years, with the latest figure at $43.6 million for Q4 2025.

  • For Q4 2025, Operating Leases rose 8.46% year-over-year to $43.6 million; the TTM value through Dec 2025 reached $43.6 million, up 8.46%, while the annual FY2025 figure was $43.6 million, 8.46% up from the prior year.
  • Operating Leases for Q4 2025 was $43.6 million at Immunocore Holdings, up from $41.4 million in the prior quarter.
  • Across five years, Operating Leases topped out at $44.4 million in Q2 2025 and bottomed at $31.8 million in Q4 2022.
  • The 4-year median for Operating Leases is $40.5 million (2024), against an average of $38.9 million.
  • The largest YoY upside for Operating Leases was 27.48% in 2025 against a maximum downside of 0.31% in 2025.
  • A 4-year view of Operating Leases shows it stood at $31.8 million in 2022, then grew by 12.13% to $35.6 million in 2023, then rose by 12.78% to $40.2 million in 2024, then grew by 8.46% to $43.6 million in 2025.
  • Per Business Quant, the three most recent readings for IMCR's Operating Leases are $43.6 million (Q4 2025), $41.4 million (Q3 2025), and $44.4 million (Q2 2025).